)

Kezar Life Sciences (KZR) investor relations material
Kezar Life Sciences Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
Focused on developing zetomipzomib for autoimmune hepatitis after terminating other clinical programs, with ongoing regulatory engagement following FDA removal of a clinical hold on a key trial in July 2025.
Type C meeting with FDA requested for Q4 2025 to discuss registration-enabling trial design.
PORTOLA Phase 2a data selected for oral presentation at The Liver Meeting 2025.
Zung To promoted to Chief Development Officer, strengthening clinical development leadership.
No product sales to date; operations funded by equity, debt, and a collaboration with Everest Medicines, with continued significant operating losses expected.
Financial highlights
Net loss for Q2 2025 was $13.7 million, down from $21.5 million in Q2 2024; six-month net loss was $30.3 million, down from $43.2 million year-over-year.
Operating expenses for Q2 2025 were $14.6 million, a decrease from $23.4 million in Q2 2024, mainly due to lower R&D and restructuring costs.
Cash, cash equivalents, and marketable securities totaled $100.8 million as of June 30, 2025, down from $132.2 million at December 31, 2024.
R&D expenses for Q2 2025 decreased to $9.6 million from $16.3 million in Q2 2024, mainly due to lower clinical activity and personnel costs.
G&A expenses for Q2 2025 decreased to $5.0 million from $5.6 million in Q2 2024.
Outlook and guidance
Cash resources are expected to fund operations for at least 12 months from the reporting date, but additional capital will be needed for long-term plans.
Expenses are expected to remain stable in the near term, then increase as zetomipzomib advances into later-stage development.
On track with clinical development and regulatory submission plan for zetomipzomib in autoimmune hepatitis.
Type C FDA meeting in Q4 2025 expected to be a key milestone for advancing zetomipzomib.
No revenue from product sales anticipated in the near future; future funding needs depend on clinical progress and regulatory outcomes.
Next Kezar Life Sciences earnings date

Next Kezar Life Sciences earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage